Looking Forward in EGFR+ and KRAS+ NSCLC

Andreas Saltos, MD, medical oncologist and clinical research medical director in the department of thoracic oncology at Moffitt Cancer Center, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer (NSCLC).

Approximately 40%-50% of patients with NSCLC harbor KRAS or EGFR mutations. Due to his alarmingly high number, Saltos notes the importance of a phase 1/1B trial (NCT01859026) which was created to examine the efficacy and safety of the combination of erlotinib (Tarceva) and binimetinib (Mektovi) for patients with EGFR and KRAS-mutated NSCLC.

Investigators continue to evaluate new combinations and develop clinical trials for this patient population to combat this disease and target KRAS and EGFR mutations.

Transcription:

0:08 | I'm excited about the fact that this is a new territory for patients with these KRAS mutations, especially where the field has exploded. There's a lot of new combinations and a lot of new trials for these patients. With any luck, a few of these combinations will start to show a lot of promise preclinically.

0:32 | There's even more exciting work being done to combat the problems of early development of resistance, where I think some time on the horizon, there will be a day where patients with KRAS mutations and EGFR mutations will really be able to have quality targeted therapy that can control the disease for a long time.